18 active not recruiting. 18 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Active not recruiting 18 |
| Phase 2 | 7 | Active not recruiting 7 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions Vancomycin (IV) - Healthy Volunteer, Hypersensitivity Reactions | Phase 1 / Phase 2 | Active not recruiting | Johns Hopkins University | 25 | 2026-05-21 | 2026-10-27 |
| The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2 - Atopic Dermatitis (AD) | Phase 1 | Active not recruiting | Daniel Kaplan | 8 | 2025-07-17 | 2026-10-06 |
| An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis APG777, APG990, Dupilumab - Atopic Dermatitis | Phase 1 | Active not recruiting | Apogee Therapeutics, Inc. | 86 | 2025-06-04 | 2026-10-13 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants GB-7624, Placebo - Atopic Dermatitis (AD) | Phase 1 | Active not recruiting | Generate Biomedicines | 40 | 2025-03-27 | 2025-12-05 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma APG777, Placebo - Asthma | Phase 1 | Active not recruiting | Apogee Therapeutics, Inc. | 31 | 2025-03-27 | 2026-10-13 |
| A Study of Single Dose of LP-003 in Healthy Adult Subjects LP-003 200mg, Placebo - Chronic Spontaneous Urticaria | Phase 1 | Active not recruiting | Longbio Pharma | 12 | 2024-10-23 | 2025-12-18 |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma AMG 691, Placebo - Asthma | Phase 1 | Active not recruiting | Amgen | 21 | 2024-10-16 | 2026-10-30 |
| Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy linvoseltamab, dupilumab - Food Allergy | Phase 1 | Active not recruiting | Regeneron Pharmaceuticals | 6 | 2024-05-17 | 2026-06-26 |
| A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD GB-0895 (SC), Placebo (SC) - Asthma, COPD (Chronic Obstructive Pulmonary Disease) | Phase 1 | Active not recruiting | Generate Biomedicines | 156 | 2023-12-12 | 2025-11-05 |
| Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16 or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Active not recruiting | Xentria, Inc. | 32 | 2023-11-10 | 2026-10-02 |
| Evaluate the Safety, Tolerability of BAT6026 Monoclonal antibody BAT6026, sodium chloride injection - Dermatitis, Atopic | Phase 1 / Phase 2 | Active not recruiting | Bio-Thera Solutions | 33 | 2023-11-09 | 2026-10-02 |
| Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients ADX-324, Placebo - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 53 | 2022-12-14 | 2026-06-16 |
| Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects VLP Peanut, Placebo - Peanut Allergy | Phase 1 | Active not recruiting | Allergy Therapeutics | 46 | 2022-10-17 | 2026-03-13 |
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331 - Hereditary Angioedema, HAE | Phase 1 / Phase 2 | Active not recruiting | BioMarin Pharmaceutical | 44 | 2022-02-15 | 2024-05-16 |
| Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA - Asthma, Nonadherence, Medication | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 60 | 2021-12-16 | 2026-08-19 |
| NTLA-2002 in Adults With Hereditary Angioedema (HAE) Biological NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | Intellia Therapeutics | 37 | 2021-12-10 | 2026-09-25 |
| Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood Cholecalciferol D3, Placebo tablet - Asthma | Phase 1 | Active not recruiting | Copenhagen Studies on Asthma in Childhood | 600 | 2009-03-01 | 2026-03-19 |
| Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood n-3 fatty acid, olive oil - Asthma, Eczema | Phase 1 | Active not recruiting | Copenhagen Studies on Asthma in Childhood | 800 | 2008-11-26 | 2026-06-05 |
Asthma (6) · Dermatitis, Atopic (4) · Angioedemas, Hereditary (3) · Eczema (3) · Chronic Urticaria (1) · Food Hypersensitivity (1) · Infections (1) · Medication Adherence (1) · Peanut Hypersensitivity (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Sounds (1) · Sarcoidosis, Pulmonary (1) · SeSAME syndrome (1)
Immune System Diseases (18) · Hypersensitivity, Immediate (16) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Bronchial Diseases (6) · Dermatitis (6) · Lung Diseases, Obstructive (6) · Respiratory Hypersensitivity (6) · Skin Diseases, Eczematous (6) · Skin Diseases, Genetic (4)
Sodium Chloride (2) · dupilumab (2) · Fatty Acids, Omega-3 (1) · Formoterol Fumarate (1) · Olive Oil (1) · RNA, Small Interfering (1) · Vancomycin (1)
Apogee Therapeutics, Inc. (2) · Copenhagen Studies on Asthma in Childhood (2) · Generate Biomedicines (2) · ADARx Pharmaceuticals, Inc. (1) · Allergy Therapeutics (1) · Amgen (1) · Bio-Thera Solutions (1) · BioMarin Pharmaceutical (1) · Daniel Kaplan (1) · Intellia Therapeutics (1) · Johns Hopkins University (1) · Longbio Pharma (1) · Regeneron Pharmaceuticals (1) · Washington University School of Medicine (1) · Xentria, Inc. (1)
United States (10) · Australia (6) · United Kingdom (5) · Denmark (3) · Canada (2) · China (2) · Germany (2) · New Zealand (2) · Spain (2) · Belgium (1) · Czechia (1) · France (1) · Netherlands (1) · Poland (1)
Daniel Kaplan, MD, PhD (1) · James G Krings, MD MSc (1) · Lauge Farnaes, MD (1) · Melanie Dispenza, MD, PhD (1) · Pieter-Jan De Kam, PhD (1)
PMID 36184023, PMID 41422501, PMID 26813208, PMID 28029926, PMID 29077711, PMID 30181143, PMID 30418579, PMID 31381020, PMID 32091548, PMID 33289844, PMID 33653805, PMID 34927195, PMID 35105560, PMID 36471430, PMID 37380711, PMID 37696621, PMID 38072183, PMID 38294975, PMID 38569788, PMID 39077939, PMID 39196551, PMID 39445704, PMID 39756833, PMID 40865727, PMID 41771441, PMID 42149595, PMID 42463642
2008 (1), 2023 (1), KL2TR002346 (1), R21AI182531 (1), UL1TR002345 (1)